Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczema that significantly affects patients’ quality of life. It is traditionally treated with…
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczema that significantly affects patients’ quality of life. It is traditionally treated with…
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the key treatment goals are to protect the skin barrier, reduce inflammation, and alleviate itch…
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin, which typically develops in early childhood and can persist into adulthood. The…
Atopic dermatitis is a common skin disease that significantly affects quality of life. For many years, atopic dermatitis treatment in China included only conventional topical/systemic agents and no…
Atopic dermatitis is a common skin disease that significantly affects quality of life. For many years, atopic dermatitis treatment in China included only conventional topical/systemic agents and no…
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin, which typically develops in early childhood and can persist into…
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin; it typically develops in early childhood and can persist into…
DRG Epidemiology’s coverage of atopic dermatitis/atopic eczema (AD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Atopic dermatitis (AD) disproportionately affects children and adolescents, and its intermittent flares of itchy rash profoundly affect their quality of life. Most pediatric patients use prescribed…
Following the 2017 launches of two atopic dermatitis novel therapies, Pfizer’s topical PDE-4 inhibitor Eucrisa (crisaborole) and Sanofi/Regeneron’s IL-4/13 inhibitor Dupixent (dupilumab), the U…
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus, eczema, and, in some cases, disrupted sleep and poor quality of life. Topical agents (e.g.,…
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus, eczema, and, in some cases, disrupted sleep and poor quality of life. Topical agents (e.g.,…
Topical corticosteroids, topical calcineurin inhibitors, and systemic immunosuppressants have historically served as the backbone of atopic dermatitis (AD) treatment. Last year, two new options…
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…